Ipilimumab-话题@MedSci

#Ipilimumab#

50篇内容 | 2506人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1365744, encodeId=9ef61365e441d, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=The Lancet Oncology：Ipilimumab用于不可切除或转移性黑素瘤, objectType=article, longId=93765, objectId=abc293e65a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abc293e65a6, replyNumber=0, likeNumber=57, createdTime=2017-03-30, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abc293e65a6, moduleTitle=The Lancet Oncology：Ipilimumab用于不可切除或转移性黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abc293e65a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365743, encodeId=4beb1365e43ee, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=CLIN CANCER RES：Ipilimumab联合放疗与机体免疫的相关性, objectType=article, longId=93452, objectId=880d934525e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=880d934525e, replyNumber=0, likeNumber=65, createdTime=2017-03-27, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=880d934525e, moduleTitle=CLIN CANCER RES：Ipilimumab联合放疗与机体免疫的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=880d934525e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365742, encodeId=7f651365e42c9, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=Lancet子刊：Nivolumab联合ipilimumab治疗晚期非小细胞肺癌效果显著, objectType=article, longId=83641, objectId=98ee83641e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98ee83641e8, replyNumber=0, likeNumber=57, createdTime=2016-12-07, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98ee83641e8, moduleTitle=Lancet子刊：Nivolumab联合ipilimumab治疗晚期非小细胞肺癌效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98ee83641e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365741, encodeId=f4841365e418d, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=NEJM：ipilimumab辅助治疗III期黑色素瘤患者，疗效显著, objectType=article, longId=79606, objectId=f1b4e9606a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1b4e9606a6, replyNumber=0, likeNumber=68, createdTime=2016-10-10, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1b4e9606a6, moduleTitle=NEJM：ipilimumab辅助治疗III期黑色素瘤患者，疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1b4e9606a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365740, encodeId=f9da1365e408e, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=Lancet Oncol：2期试验支持nivolumab+ipilimumab作为晚期黑色素瘤一线治疗（CheckMate 069）, objectType=article, longId=77259, objectId=1a9fe7259eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a9fe7259eb, replyNumber=0, likeNumber=67, createdTime=2016-09-14, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a9fe7259eb, moduleTitle=Lancet Oncol：2期试验支持nivolumab+ipilimumab作为晚期黑色素瘤一线治疗（CheckMate 069）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a9fe7259eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365739, encodeId=c1d81365e3960, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=NEJM：Ipilimumab治疗异基因造血干细胞移植（HSCT）后的复发初见成效, objectType=article, longId=72960, objectId=c6f7e296071, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6f7e296071, replyNumber=0, likeNumber=75, createdTime=2016-07-18, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6f7e296071, moduleTitle=NEJM：Ipilimumab治疗异基因造血干细胞移植（HSCT）后的复发初见成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6f7e296071)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365738, encodeId=32421365e3893, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=Ann Rheum Dis：Ipilimumab、nivolumab增加癌症患者自身免疫性关节和组织病, objectType=article, longId=71823, objectId=0a88e182394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a88e182394, replyNumber=0, likeNumber=74, createdTime=2016-07-01, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a88e182394, moduleTitle=Ann Rheum Dis：Ipilimumab、nivolumab增加癌症患者自身免疫性关节和组织病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a88e182394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365737, encodeId=81871365e3717, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), objectType=article, longId=71408, objectId=4379e1408e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4379e1408e0, replyNumber=0, likeNumber=42, createdTime=2016-06-23, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4379e1408e0, moduleTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4379e1408e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365736, encodeId=8ac41365e36b8, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=招募患者：ipilimumab与化疗联合和单纯化疗治疗小细胞肺癌患者的疗效比较, objectType=article, longId=56008, objectId=30c256008d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30c256008d1, replyNumber=0, likeNumber=78, createdTime=2015-09-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30c256008d1, moduleTitle=招募患者：ipilimumab与化疗联合和单纯化疗治疗小细胞肺癌患者的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30c256008d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365735, encodeId=2e431365e3512, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=NEJM：Nivolumab联合Ipilimumab用于晚期黑素瘤疗效优于单药治疗, objectType=article, longId=49754, objectId=de8f49e54b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de8f49e54b6, replyNumber=0, likeNumber=111, createdTime=2015-04-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de8f49e54b6, moduleTitle=NEJM：Nivolumab联合Ipilimumab用于晚期黑素瘤疗效优于单药治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de8f49e54b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365734, encodeId=6dd21365e34bf, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=Lancet Oncology：Ipilimumab延长晚期黑色素瘤术后患者生存期, objectType=article, longId=49652, objectId=a76c496528e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a76c496528e, replyNumber=0, likeNumber=74, createdTime=2015-04-23, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a76c496528e, moduleTitle=Lancet Oncology：Ipilimumab延长晚期黑色素瘤术后患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a76c496528e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1365733, encodeId=7f181365e33ad, content=<a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a>, objectTitle=NEJM：晚期黑色素瘤治疗效果，Pembrolizumab V.S Ipilimumab, objectType=article, longId=49604, objectId=874149604c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=874149604c0, replyNumber=0, likeNumber=76, createdTime=2015-04-22, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=874149604c0, moduleTitle=NEJM：晚期黑色素瘤治疗效果，Pembrolizumab V.S Ipilimumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=874149604c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Ipilimumab

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

The Lancet Oncology：Ipilimumab用于不可切除或转移性黑素瘤

2017-03-30

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

CLIN CANCER RES：Ipilimumab联合放疗与机体免疫的相关性

2017-03-27

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

Lancet子刊：Nivolumab联合ipilimumab治疗晚期非小细胞肺癌效果显著

2016-12-07

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

NEJM：ipilimumab辅助治疗III期黑色素瘤患者，疗效显著

2016-10-10

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

Lancet Oncol：2期试验支持nivolumab+ipilimumab作为晚期黑色素瘤一线治疗（CheckMate 069）

2016-09-14

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

NEJM：Ipilimumab治疗异基因造血干细胞移植（HSCT）后的复发初见成效

2016-07-18

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

Ann Rheum Dis：Ipilimumab、nivolumab增加癌症患者自身免疫性关节和组织病

2016-07-01

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029)

2016-06-23

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

招募患者：ipilimumab与化疗联合和单纯化疗治疗小细胞肺癌患者的疗效比较

2015-09-11

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

NEJM：Nivolumab联合Ipilimumab用于晚期黑素瘤疗效优于单药治疗

2015-04-24

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

Lancet Oncology：Ipilimumab延长晚期黑色素瘤术后患者生存期

2015-04-23

circumcision (审核中...)

前往app查看评论内容

#Ipilimumab#

NEJM：晚期黑色素瘤治疗效果，Pembrolizumab V.S Ipilimumab

2015-04-22

科室
- - 订阅+
  - 更多科室
工具
服务